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https://doi.org/10.1016/j.ccell.2017.10.003SUMMARYCytotoxic T cells infiltrating tumors are thought to utilize HIF transcription factors during adaptation to the
hypoxic tumor microenvironment. Deletion analyses of the two key HIF isoforms found that HIF-1a, but
not HIF-2a, was essential for the effector state in CD8+ T cells. Furthermore, loss of HIF-1a in CD8+ T cells
reduced tumor infiltration and tumor cell killing, and altered tumor vascularization. Deletion of VEGF-A, an
HIF target gene, in CD8+ T cells accelerated tumorigenesis while also altering vascularization. Analyses of
human breast cancer showed inverse correlations between VEGF-A expression and CD8+ T cell infiltration,
and a link between T cell infiltration and vascularization. These data demonstrate that the HIF-1a/VEGF-A
axis is an essential aspect of tumor immunity.INTRODUCTION
Hypoxia-inducible transcription factors (HIFs) have a central
role in physiological adaptation to varying oxygenation states.
They act as essential controls for adaptive changes at the
cellular, tissue, and organismal levels in response to a range
of challenges, including altered tissue oxygenation (Semenza,
2012). Two HIF transcription factors comprise the best charac-
terized elements of this response: both are oxygen sensitive
and in both cases their activity can be regulated post-transcrip-
tionally, via the von Hippel-Lindau (VHL) tumor-suppressor
complex and the FIH asparagine hydroxylase. The first element
of the pathway to be cloned was the HIF-1a factor; it is ex-
pressed in most if not all mammalian cell types. It has important
functional roles in both innate and adaptive immune cells,
including macrophages (Cramer et al., 2003), neutrophils
(Walmsley et al., 2005), dendritic cells (Jantsch et al., 2008),Significance
Cytotoxic T lymphocytes respond to the immune microenviron
lated in significant part by the hypoxia-inducible transcriptio
response in T cells has direct effects on cancer growth, progre
tegies targeting HIF-1a or VEGF-A signaling in the tumor micro
notherapy specifically. These findings also show that modulat
fects on tumor vascularization and progression; exploi
immunotherapeutic approaches.
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This is an open access article undand lymphocytes (McNamee et al., 2013). A second well-char-
acterized element of the HIF pathway is HIF-2a: its functional
role includes regulation of erythropoiesis. The role of HIF-2a
in the immune system is less clear, but appears to be important
for the regulation of nitric oxide homeostasis in innate cells and
controlling arginase expression, among its other roles (Takeda
et al., 2010).
It has become clear that the HIF transcription factors are regu-
lated in a complex fashion and are controlled by many factors
other than oxygenation. In the immune system cytokines can
induce both HIF-1a and HIF-2a in response to a range of chal-
lenges, including inflammation and infection (reviewed in Pala-
zon et al., 2014). In T lymphocytes, HIF-1a is stabilized upon
T cell receptor (TCR) activation (Nakamura et al., 2005) and is
important for a metabolic transition to glycolysis, which in turn
supports proliferation and effector function (Buck et al., 2015;
Pearce et al., 2013).ment and tissue oxygenation. That response in turn is regu-
n factor (HIF). Here we show that that the HIF-1a/VEGF-A
ssion, and vascularization, suggesting that therapeutic stra-
environment will affect cancer therapy generally and immu-
ing the hypoxic response in cytotoxic T cells has striking ef-
tation of this knowledge could significantly advance
mber 13, 2017 ª 2017 The Authors. Published by Elsevier Inc. 669
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Hypoxia Promotes CD8+ T Cell Glycolytic Metabolism in an HIF-1a- but Not HIF-2a-Dependent Fashion
(A) qRT-PCR of mRNA levels of Hif1a and Hif2a on magnetically isolated splenic CD8+ T cells before and after activation with aCD3/CD28 for the indicated time
points (n = 3). US, unstimulated. Error bars represent SD.
(B) Immunoblots showing HIF-1a and HIF-2a expression in T cells collected at the indicated time points after activation. Densitometric analyses are shown at the
bottom.
(C) Deletion efficiency of Hif1a and Hif2a in genomic DNA from CD8+ lymphocytes isolated from HIF-1afl/fldlckCRE or HIF-2afl/fldlckCRE mice (n = 4, error bars
represent SD).
(D) CFSE (carboxyfluorescein succinimidyl ester) dilution assay 72 hr after in vitro activation (n = 3, error bars represent SD).
(E) Proliferation index and percent survival of isolated CD8+ T lymphocytes 4 days after activation (n = 4, error bars represent SD).
(F) CD8+ T cells were isolated from spleens and activated with aCD3/CD28 for 48 hr, and then expanded for 3 days in IL-2 and subjected to 21% or 1% O2 for
24 hr. Western blotting was performed on nuclear fractions; densitometric analyses are shown.
(legend continued on next page)
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Deletion of the aryl hydrocarbon nuclear translocator (ARNT)/
HIF-1b gene in CD8+ T cells impairs the expression of cytolytic
effector molecules, including perforins and granzymes, and
alters the expression of CD62L and cytokines and cytokine re-
ceptors involved in the migration of activated T cells from sec-
ondary lymphoid organs to peripheral tissues (Finlay et al.,
2012). Although the Arnt deletion has a range of effects, block-
ing the action of both the HIF-a isoforms, as well as the aryl hy-
drocarbon receptor (AhR), these experiments illustrate how
important the role of the HIF pathway in T cell function might
be. Further evidence for HIF’s role in adaptive immunity came
from experiments utilizing mice with a deletion of Vhl in CD8+
T cells. This deficiency of a key negative regulator of HIF
caused increased expression of both HIF-a isoforms and a
resultant increase in glycolytic activity, as well as increased
expression of costimulatory receptors and cytolytic molecules.
This in turn led to increased effector function (Doedens
et al., 2013).
The deletion of Vhl in T cells results in increased anti-tumor
activity in a T cell-dependent model of tumor killing. Loss of
VHL removes certain aspects of oxygen-regulated control of
expression of the HIF transcription factors; however, as noted
above, there is considerable complexity to the pathway. It is
also unclear which of the numerous targets of HIF function might
play an important role in T cell function in the tumor
microenvironment.
Arguably, the most well-studied HIF target gene is the
angiogenic/permeability vascular endothelial growth factor A
(VEGF-A), which is expressed in both tumor and stromal cells.
Although VEGF-A production by tumor cells has been correlated
with poor prognosis, pharmacological VEGF-A blockade has
shown limited therapeutic success; one likely reason is that
VEGF-A from non-endothelial stromal populations can enable
tumor survival (Shojaei et al., 2008). In previous studies, we
genetically deleted Vegfa in myeloid cells (Stockmann et al.,
2008) and fibroblasts (Kim et al., 2012); in both cases this led
to accelerated tumor growth. Tumor-infiltrating lymphocytes
secrete VEGF-A (Freeman et al., 1995); however, the contribu-
tion of T cell-derived VEGF-A to lymphocyte function and tumor
progression is not clear.
RESULTS
Hypoxia Affects CD8+ T Cell Glycolytic Metabolism in an
HIF-1a- but Not HIF-2a-Dependent Fashion
Hypoxia induces a shift toward an anaerobic and glycolytic
metabolism, and HIF function is associated with the regulation
of glycolysis (Seagroves et al., 2001) and the shift to a suppres-
sion of oxidativemetabolism (Kim et al., 2006; Papandreou et al.,(G) CD8+ T cells fromHIF-1afl/fldlckCRE (maroon), HIF-2afl/fldlckCRE (green), and litt
expanded for 5 days in the presence of IL-2, and cultured for 24 hr under 21% v
error bars represent SD).
(H) Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) o
conditions and after injection (dashed line) of oligomycin and FCCP (stressed) (n
(I and J) Supernatants of CD8+ T cells cultured as in (G) were measured for gluc
(K) Representative flow-cytometry histograms of viability staining and percent su
two-way ANOVA for multiple comparisons with Bonferroni correction.
Horizontal lines are the mean values. ****p < 0.00005, ***p < 0.0005, **p < 0.005,2006). T cell activation and proliferation are themselves corre-
lated with increased glycolysis (Buck et al., 2015). As can be
seen, TCR stimulation results in increases in Hif1a and Hif2a
mRNA expression (Figure 1A) and protein accumulation (Fig-
ure 1B). Additionally, both the normal tissue environment and
tumors have levels of oxygen that will activate the HIF pathway,
which is thought to become highly active at levels corresponding
to less than 5% oxygen in tissue culture systems (Semenza,
2012); we found by oxygen electrode measurements that murine
spleens have a mean pO2 of approximately 22 mmHg, which
would approximate a tissue culture environmental oxygen level
of approximately 3% (Table S1). Solid tumors are known to
havemuch lower pO2 values, ranging well below 10mmHg (Vau-
pel et al., 1989). Thus, HIF response will affect T cells in both
normal and malignant tissues.
To study the effects of HIF-1a and HIF-2a in CD8+ T cells, we
genetically ablated exon2 from the Hif1a (Ryan et al., 2000) or
Epas alleles (Gruber et al., 2007) by a Cre-recombinase ex-
pressed under the control of the distal promoter of the lympho-
cyte protein tyrosine kinase gene (dlck) (HIF-1afl/fldlckCRE and
HIF-2afl/fldlckCRE); this transgene is expressed at a late stage
of T cell development (Zhang et al., 2005; Zhang and Bevan,
2010). This strategy results in a complete deletion of Hif1a
and Hif2a in CD8+ T cells (Figure 1C) and does not affect
T cell proliferation or survival at 72 hr after activation in 21% ox-
ygen conditions (Figures 1D and 1E). Deletion in CD4+ T cells in
this model occurs to a lesser extent (Zhang et al., 2005) (Fig-
ure S1). We cultured mutant and control cytotoxic T lympho-
cytes (CTLs) under normoxic (21% O2) and hypoxic (1% O2)
conditions (Figure 1F). As CD8+ T cells differentiated into effec-
tors, CD8+ T cells lacking HIF-1a, but not HIF-2a, showed
impaired expression of genes involved in glycolytic metabolism
(Figure 1G). HIF-1a plays an essential role in the maintenance
of glycolysis, as shown by extracellular flux analyses (Fig-
ure 1H), and glucose uptake and lactate production (Figures
1I and 1J). CD8+ T cells lacking HIF-2a have a normal glycolytic
metabolism and metabolic shift during hypoxic treatment (Fig-
ures 1H–1J). Hypoxia and loss of HIF-1a, but not HIF-2a,
modestly decreased the survival of terminally differentiated
CD8+ CTLs (Figure 1K).
Hypoxia and HIF-1a Supports T Cell Acquisition of
Effector Function
HIF-1a-, but not HIF-2a-deficient effector CD8+ T cells failed to
downregulate the cell-surface expression of CD62L (Figure 2A),
a factor associated with T cell activation and migration of
CD44+ antigen-experienced cells following in vitro activation
and expansion in the presence of interleukin-2 (IL-2). Addition-
ally, HIF-1a ablation significantly decreased the production ofermate controls (black for HIF-1afl/fl, gray for HIF-2afl/fl) were isolated, activated,
ersus 1% O2. qRT-PCR was performed for Hk2, Pdk1, Mct4, and Pgk (n = 3,
f CD8+ T cells prepared as in (G) were measured by flux analysis, under basal
= 4 per genotype, error bars represent SEM).
ose (I) and lactate (J) levels (n = 6, error bars represent SD).
rvival of CD8+ T cells cultured as in (G) (n = 4). Grouped data were assessed by
*p < 0.05. See also Table S1 and Figure S1.
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the effector cytokines interferon g (IFNg) and tumor necrosis
factor a (TNFa) by CTLs (Figure 2B). Hypoxia increased the pro-
duction of the cytolytic molecule granzyme B (Figure 2B) and
the expression of the activation-related costimulatory mole-
cules CD137, OX40, and GITR, and checkpoint receptors
PD-1, TIM3, and LAG3. These changes occurred in an
HIF-1a-, but not HIF-2a-dependent manner following in vitro
activation and addition of IL-2 (Figures 2B–2E). This is in line
with our previous findings supporting a model in which HIFa
isoform usage and the targets regulated are dependent on
cytokine milieu. Interestingly, CD8+ T cells lacking either both
VHL and HIF-1a or both HIF-1a and HIF-2a failed to downregu-
late surface expression of CD62L and acquire an effector
phenotype after activation (Figures S2A–S2H). These defects
had an impact on the cytotoxic capacity of antigen-specific
HIF-mutant CD8+ T cells, which showed a reduced ability to
kill target cells in vitro (Figure S2I).
As can be seen in Figure 2F, VEGF-A production increased
with T cell activation, and T cell culture under 1% O2 condi-
tions further increased VEGF-A secretion. This expression
was shown by deletion analysis to be driven by HIF-1a, but
not HIF-2a, following expansion in IL-2 (Figure 2G). T cell-
derived Vegfa is likely a significant source of the growth factor
in immune infiltrates; Figure 2H shows that T cells infiltrating
Lewis lung carcinoma (LLC) tumors express Vegfa to a
level comparable with the levels of expression in F4/80+
macrophages.Genetic Deletion of HIF-1a in T Lymphocytes Leads to
Accelerated Tumor Growth Characterized by Impaired
CD8+ T Cell Infiltration
To determine the role played by the HIF pathway in polyclonal
CD8+ T cells during tumor growth, we subcutaneously grafted
LLC and B16-F10 melanoma cells into mice specifically lacking
HIF-1a or HIF-2a in T lymphocytes (HIF-1afl/fldlckCRE or
HIF-2afl/fldlckCRE), and compared tumor growth with that seen
in wild-type (WT) control littermates (HIF-1afl/fl and HIF-2afl/fl).
Tumors growing in mice lacking HIF-1a in T cells expanded
more rapidly (Figures 3A and 3B) and were significantly larger
at endpoint (Figure 3C). This was not true for tumors grown in
HIF-2a-deficient animals.Figure 2. Hypoxia and HIF-1a, but Not HIF-2a, Support CD8+ T Cell Ac
(A) CD8+ T cells were isolated from spleens of HIF-1afl/fldlckCRE (maroon) or
with aCD3/CD28 for 48 hr, then expanded for 5 days in IL-2 and subjected to 21%
(B) Intracellular expression of IFNg, TNFa, and granzyme B in HIF-1afl/fldlckCR
restimulation (n = 3, error bars represent SD).
(C) Intracellular expression of IFNg, TNFa, and granzyme B in HIF-2afl/fldlckC
restimulation (n = 3, error bars represent SD).
(D) Surface expression of costimulatory molecules/checkpoint receptors CD1
HIF-1afl/fldlckCRE (maroon) HIF-1afl/fl control littermates (black), activated and ex
(E) Same as in (D) on CD8+ T cells isolated from HIF-2afl/fldlckCRE (green) or HIF-
(F) Relative mRNA levels of Vegfa (left, n = 3) and amount of VEGF-A in media (rig
after aCD3/CD28 activation.
(G) Amount of VEGF-A in media from CTLs expanded as in (A) and cultured und
(H) Relative expression of Vegfa in total LLC tumor lysate and immune populations
implantation (n = 10, error bars represent SD).
Grouped data were assessed by two-way ANOVA for multiple comparisons with B
mean fluorescence intensity. See also Figure S2.The composition of tumor-infiltrating lymphocytes in these
experimental tumors was lower in CD8+ T cells in mice deficient
in HIF-1a in T cells, and there was a diminished CD8+-to-CD4+
T cell ratio (Figure 3D). HIF-1a-deficient tumor-infiltrating CD8+
lymphocytes were characterized by a drop in expression of the
costimulatorymolecules CD137 andGITR, and in the checkpoint
receptors PD-1, LAG3, and TIM3 (Figure 3E). The HIF-1a-depen-
dent reduction in PD-1 seen in tumor-infiltrating lymphocytes is
surprising given that previous work in chronic viral infection
found PD-1 expression to be HIFa independent, but this result
may reflect model-specific differences, such as inflammatory
milieu, between tumor and systemic chronic viral infections
(Doedens et al., 2013).
Moreover, FOXP3-expressing CD4+ T cells were enriched in
the mutant mice, leading to a decreased IFNg+/FOXP3+ ratio
(Figure 3F). This is consistent with recent reports highlighting
the role of HIF-1a in the promotion of IFNg production by CD4+
T cells (Lee et al., 2015), and the regulation of FOXP3 degrada-
tion by HIF-1a (Dang et al., 2011).
As described above, there are lower numbers of CD8+ T cells
in tumors from animals where T cells lack HIF-1a. This may be
in part related to a deficient capacity to traverse endothelial
barriers. To determine how HIF-1a expression in CD8+ T cells
affects migration through endothelium, we performed in vitro
coculture experiments in which activated primary WT control
or mutant CD8+ T cells were isolated and cultured in hypoxic
conditions in a Boyden chamber. The Boyden chamber used
for these experiments was lined with early-passage murine pri-
mary WT pulmonary endothelial cells. Under these conditions
CD8+ T cells lacking HIF-1a have a significantly reduced rate
of migration, with less than half as many mutant T cells on
the other side of the barrier relative to the number of WT
T cells after 24 hr of culture under hypoxia (Figure 3G).
To further characterize tumor vascularization in animals with
HIF-mutant T cells, we injected mutant and control LLC tumor-
bearing mice with fluorescence-conjugated tomato lectin.
Tumor vascularization was then characterized by image detec-
tion algorithms, which showed that tumors in mutant mice
differed significantly in the length of vascular segments between
branch points, had altered vascular architecture (vessel straight-
ness), and showed a trend to an increase in the overall amount of
patent endothelium (Figures 3H and 3I). Increased vessel lengthquisition of Effector Phenotype
HIF-2afl/fldlckCRE (green) and littermate control (black) mice, and activated
or 1%O2 for 24 hr. Expression of CD44 andCD62L by flow cytometry is shown.
E (maroon) and HIF-1afl/fl control littermates (black) by flow cytometry after
RE (green) and HIF-2afl/fl control littermates (gray) by flow cytometry after
37, OX40, GITR, PD-1, TIM-3, and LAG3 on CD8+ T cells isolated from
panded as in (A) (n = 3, error bars represent SD).
2afl/fl control littermate mice (gray) (n = 3, error bars represent SD).
ht, n = 4, error bars represent SD) on CD8+ T cells for the indicated time points
er 21% O2 or 1% O2 for 24 hr (n = 4, error bars represent SD).
isolated from subcutaneous Lewis lung carcinoma (LLC) tumors 11 days after
onferroni correction. ****p < 0.00005, ***p < 0.0005, **p < 0.005, *p < 0.05. MFI,
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Figure 3. Genetic Deletion of HIF-1a, but Not HIF-2a, in T Lymphocytes Leads to Accelerated Tumor Growth and Impaired CD8+ T Cell Tumor
Infiltration
(A and B) Growth curves of subcutaneous LLC and B16-F10 tumors (0.5 3 106 cells/mouse) in HIF-1a mutant mice (maroon) and littermate controls (black)
(A, n = 10–13 per group) or HIF-2amutant mice (green) versus littermate controls (black) (B, n = 6–17 per group). Statistical analysis was performed by two-way
ANOVA with Sidak correction for multiple comparisons; tumor volumes are shown (mean values ± SEM).
(C) Tumor weights at the endpoint of the experiment (error bars represent SD).
(D) Representative dot plots showing CD8+ and CD4+ T cell tumor infiltration in mutant mice and littermate controls by flow cytometry (left) and CD8+ to CD4+ ratio
in TILs (right, n = 6, error bars represent SD).
(E) Expression of costimulatory receptors and checkpoint inhibitors on CD8+ T cells infiltrating LLC isografts 13 days after subcutaneous inoculation (n = 6, error
bars represent SD).
(F) Flow-cytometry analyses on CD4+ TILs: IFNg+ cells, percent FOXP3+ cells, and IFNg+/FOXP3+ CD4+ T cell ratio (n = 6, error bars represent SD).
(G) HIF-1a-deficient (maroon) and control (black) CD8+ T cells were subjected to 1% O2 and cultured in a Boyden chamber on top of a confluent layer of primary
endothelial cells. Twelve hours later T cells in the bottom well were counted (n = 4, error bars represent SD).
(H) Immunofluorescence images from LLC tumors for the indicated genotypes (blue = DAPI, red = tomato lectin-Dylight-594).
(I) Analyses of tomato lectin-Dylight-594-stained LLC tumor sections: mean vessel length, percent covered area, and vessel straightness. The means of these
parameters per mouse are shown (6 fields per mouse, nR 6 mice per group, error bars represent SEM).
****p < 0.00005, ***p < 0.0005, **p < 0.005, *p < 0.05; n.s., not significant.
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and tumor perfusion and decreased tortuosity are hallmarks of
vascular normalization.
Genetic Deletion of HIF-1a in T Lymphocytes Results in
Loss of Anti-tumor Activity in Models of Cancer
Immunotherapy
To determine whether HIF-1a affects the acquisition of effector
function in an antigen-specific model, we used transgenic OT-I
expressing mice (Hogquist et al., 1994) with conditional HIF-1a
mutations, and with or without dlckCRE expression, to obtain
CD8+ T cells; these were then activated with cognate SIINFEKL
peptide. Similar to the polyclonal aCD3/CD28 activated CD8+
T cells, these transgenic T cells were able to proliferate and sur-
vive during the differentiation into effectors (Figure S3A), but had
defects in CD62L downregulation (Figures 4A and S3B). HIF-1a
mutant T cells also have altered granzyme B, TNFa, and IFNg
production after antigenic restimulation (Figures S3C and S3D),
and expression of costimulatory/checkpoint receptors (Figures
4B and S3E), which was dependent on the level of oxygenation
(Figure 4B). This is an important observation given the levels of
oxygen present in lymphoid organs and solid tumors
(Table S1). We checked the ability of HIF-1a-deficient OT-1 cells
to migrate in vivo by cotransferring control CD45.1+ and mutant
CD45.1+ TdTomato+ CD8+ T cells into CD45.2 hosts bearing
B16-OVA tumors, then determining the relative percentage of
each genotype of the transferred cells present in spleens, lymph
nodes, and tumors 48 hr after adoptive transfer. HIF-1a-deficient
T cells show both increased migration to lymphoid organs and a
defect in homing to tumors (Figure 4C). When HIF-1a-deficient
OT-I cells were transferred into B16-OVA tumor-bearing WT
recipient mice, they were completely deficient in their ability to
control tumor growth, leading to decreased survival (Figure 4D).
Importantly, HIF-1a mutant mice harboring MC38 colon carci-
noma tumors had a significantly inhibited response to aPD-1
and aCTLA4 combinatorial antibody-based immunotherapy
relative to control WT littermates (Figure 4E).
CD8A mRNA in Human Breast Cancer Inversely
Correlates with VEGF-A Expression
Based on our finding that loss of HIF-1a in T cells leads to
decreased T cell infiltration and alterations in tumor vasculari-
zation, and given the high levels of VEGF-A produced by
CD8+ T cells, we investigated the correlations between the
presence of total VEGFA transcripts and immunogenes in pri-Figure 4. HIF-1a Is Necessary for Effector CD8+ T Cell Function and M
(A) CD8+ T cells were isolated from spleens of OT-1 HIF-1afl/fldlckCRE (maroon) an
then expanded for 5 days in the presence of IL-2 and subjected to 21%, 5%,
expression of CD44 and CD62L (n = 3).
(B) Expression of intracellular granzyme B and the indicated costimulatory molec
(C) Left: diagram outlining the in vivomigration experiment: representative flow-c
HIF-1a mutant (CD45.1+/TdTomato+, maroon) and control (CD45.1+, black) OT-1
nodes (LN), and tumors were collected 48 hr after the adoptive cell cotransfer an
(error bars represent SD, n = 6).
(D) 13 106 OT-1 cells were transferred into recipient mice harboring B16-OVA tum
statistical analysis by log-rank (Mantel-Cox) test; error bars represent SEM.
(E) Tumor growth curves of MC38 tumor cells subcutaneously injected into HIF-1
antibodies (left, n = 3) or a combination of aPD-1 and aCTLA4 blocking antibod
performed by two-way ANOVA with Sidak correction for multiple comparisons. T
****p < 0.00005, **p < 0.005, *p < 0.05; n.s., not significant. See also Figure S3.
676 Cancer Cell 32, 669–683, November 13, 2017mary human breast cancer samples from a cohort of patients
with breast cancer (the Uppsala cohort) (Miller et al., 2005). Fig-
ure 5A shows the correlation of transcription abundance values
of CD8A versus VEGFA, carbonic anhydrase 9 (CA9), and
endothelial metagene probes in the Uppsala cohort. The pres-
ence of VEGFA transcript in primary tumors negatively corre-
lates with immunogenes associated with T cell infiltration.
Among all tested pairwise comparisons between immunogenes
and VEGFA, CD8A has the highest Spearman negative correla-
tion. Figure 5B shows the correlation of CD8A versus VEGFA in
different breast cancer subtypes. To further explore the clinical
significance of these findings, we investigated the disease-free
specific survival classified by breast cancer subtype according
to the levels of VEGFA and CD8A transcript abundance in the
Uppsala cohort (Figure S4). We then studied potential correla-
tions between the levels of CD8A and a metagene comprising
endothelial transcripts in breast cancer patients, before and
after treatment with agents targeting the VEGF/VEGF receptor
pathway: sunitinib (Figures 5C and 5D) and bevacizumab
(PROMIX phase 2 trial) (Figures 5E and 5F). As can be seen,
both treatments resulted in an increase in the expression of
CD8A, which was correlated with an increase in the expression
of the endothelial metagene.
VEGF-A Deficiency in T Lymphocytes Accelerates
Isograft Tumor Growth
Given the potential correlation between T cell responses and
tumor vascularization, we next determined how the HIF target
VEGF-A might be affecting tumor progression through its
expression in CD8+ T cells. We deleted the Vegfa gene in
T cells using the same transgenic driver of cre expression that
is described above. This efficiently ablated the production of
VEGF-A in these cells (Figures S5A–S5D); the later stage of
lymphoid deletion in the dlck-cre prevented effects on T cell
development, which were described in experiments where
VEGF-A was deleted earlier in lymphoid differentiation (Gerber
et al., 2002; Ohm et al., 2003) (Figures S5E–S5H).
To first determine whether VEGF-A affects T cell functionmore
generally, we cultured CTLs obtained from VEGFfl/fldlckCRE mice
under 21% O2 and 1% O2. These mutant cells had no alteration
of survival, glycolytic metabolism, or expression of cytolytic and
costimulatory/checkpoint receptors, relative to those same
parameters in WT cells. VEGF-A-deficient OT-1 CTLs exhibit
similar CD62L and CD44 expression levels relative to thoseigration
d littermate control (black) mice and activated with cognate peptide for 2 days,
or 1% O2 for 24 hr. Representative flow-cytometry histograms showing the
ules/checkpoint receptors on CD8+ T cells prepared as in (A).
ytometry plots are shown for each pool before and after adoptive cotransfer of
T cells into CD45.2+ B16-OVA tumor-bearing WT mice. Right: spleens, lymph
d relative percentages of migrated cells of the indicated genotypes are shown
ors (n = 6): tumor volumes (left) and overall percent survival (right) are shown;
amutant and littermate controls. Mice were treated with either isotype control
ies (right, n = 6), on days 5, 7, and 9 (dashed lines). Statistical analysis was
umor volumes are shown (mean values ± SEM).
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Figure 5. CD8A Transcript Abundance in Human Breast Cancer Positively Correlates with an Endothelial Cell Metagene
(A) Correlation analyses between VEGFA, CA9, and an endothelial metagene (PECAM, CDH5, CD34); and a set of immunogenes in the Uppsala cohort.
Colorgram of Spearman’s rank correlation matrix where the gene transcript levels are arranged according to hierarchical clustering. Red indicates positive
correlation and blue, negative correlation. CD8A versus endothelial metagene Spearman’s correlation coefficient rho = 0.191, p = 0.0023.
(B) Correlation between CD8A and VEGFA transcript abundance in the Uppsala cohort, and according to breast cancer subtype (mean values with confidence
interval).
(C) Docetaxel- and sunitinib + docetaxel-induced changes from baseline in the expression of the indicated transcripts and metagene 14 days after treatment in
breast cancer patients (vertical lines represent 95% confidence intervals).
(D) Correlations between the changes in CD8A transcript and endothelial metagene abundance from baseline to 14 days after the indicated treatments
(mean values with confidence interval).
(E) Her2-negative breast cancer patients received two cycles of epirubicin and docetaxel (ED), followed by ED plus bevacizumab for four additional cycles
(BEV + ED). Change in the expression of the indicated transcripts andmetagene from baseline to the second cycle and to surgery (top), and from the second cycle
to surgery (bottom). Multi-center, single arm, phase 2 PROMIX clinical trial; vertical lines represent 95% confidence intervals.
(F) Correlations between the changes inCD8A transcript and endothelial metagene abundance frombaseline to second cycle (epirubicin + docetaxel) and second
cycle to surgery (bevacizumab + epirubicin + docetaxel) in the PROMIX trial (mean values with confidence interval). Transcript abundance values represent
log2-transformed probe intensity values.
See also Figure S4.
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seen inWT T cells, and have only aminor reduction in expression
of costimulatory molecules (Figures S6A–S6D). This reduction
did not prevent the VEGF-A mutant cells from carrying out effi-
cient killing of ovalbumin-expressing target cells in an in vitro
assay (Figure S6E).
To determine whether directed killing of tumor cells by T cells
was influenced by expression of VEGF-A, we adoptively trans-
ferred VEGFfl/fldlckCRE or WT CTLs to mice harboring B16-OVA
tumors. VEGF-A deficiency only marginally affected tumor
growth in this model (Figure 6A). Directed tumor cell killing by
T cells is not affected by the loss of T cell VEGF-A, indicating
that this aspect of HIF-1a function is not VEGF-A dependent.
Subcutaneous LLC tumors grew at a faster rate in VEGFfl/fl
dlckCREmutantmice than that seen inWTcontrolmice (Figure6B),
at rates comparable with the tumor growth rate in mice lacking
VEGF-A in the myeloid compartment (VEGFfl/flLysMCRE, Figures
S6F and S6G). This latter observation was previously docu-
mented as being related to an increased degree of tumor perfu-
sion (Stockmann et al., 2008), which led to significantly increased
tumor weights in myeloid VEGF-A null animals at endpoint.
Analyses of the composition of polyclonal tumor-infiltrating
lymphocytes lacking VEGF-A revealed a decreased rate of
CD8+ T cells migrating into LLC tumors (Figure 6C). In contrast
to HIF-1a-deficient tumor-infiltrating CD8+ T cells, however,
PD-1 expression in VEGF-deficient tumor-infiltrating lympho-
cytes (TILs) is unaffected (Figure 6D) and there are no changes
in FOXP3 expression levels in infiltrating CD4+ T cells (Figure 6E).
Tumor vessels inmice lacking T cell-derived VEGF-A exhibited
some of the hallmarks of normalization, including increased
perfusion and segment length between branch points, and
decreased tortuosity (Figure 6F), as well as increased pericyteFigure 6. VEGF-A Deletion in T Lymphocytes Accelerates Tumor Grow
(A) 1 3 106 OT-1 cells of the indicated genotype were adoptively transferred into
recipient mice (error bars represent SE). Right: overall survival.
(B) Left: representative growth curve of subcutaneously injected LLC tumors in VE
mice (black) (0.5 3 106 tumor cells/mouse) (error bars represent SE). Right: tu
represent SD).
(C) Representative dot plots showing CD8+ and CD4+ polyclonal T cell LLC tu
cytometry. Right: CD8+ to CD4+ ratio in TILs (n = 6, error bars represent SD).
(D) PD-1 expression on CD8+ TILs (n = 6, error bars represent SD).
(E) Percent FOXP3+ cells on CD4+ TILs (n = 6, error bars represent SD).
(F) Left: immunofluorescence images of LLC tumor sections (blue = DAPI, red =
area, and vessel straightness of LLC tumors grafted in VEGFfl/fldlckCRE (blue) or c
parameters per mouse are shown (4 fields per mouse, 1 field = 0.8 mm2, nR 6
(G) Left: representative confocal images of LLC tumor sections for the indicate
quantification of the pericyte coverage (4–6 fields per mouse, nR 6 mice per gr
(H) Representative confocal images of LLC tumor sections stained with pimonid
(I) Quantification of percent pimonidazole+ areas in LLC isografts (nR 6 mice pe
(J) Vegfa relative expression in total LLC tumor lysates by qRT-PCR (error bars r
(K) In vitro T cell migration of VEGF-A-deficient (blue) and control (black) CD8+ T
represent SD).
(L) Flow-cytometry histograms showing the surface VE-cadherin (left) and VCAM
combinant VEGF-A (20 ng/mL, red) or control (dark blue); and surface expression
the indicated genotypes. MFI and ±SD values are shown for each histogram.
(M) Growth curve of subcutaneous LLC tumors treated with three doses of vehic
represent SEM.
(N) Time to first palpable tumors for the indicated genotypes in a transgenic m
represent SD) (left) and total tumor weights at 17 weeks of age (right, nR 17 mi
(O) H&E staining and percent PYMT-MMTV tumor progression stages for the ind
A two-tailed unpaired Student’s t test was used for comparisons. For tumor volum
for multiple comparisons. ****p < 0.00005, **p < 0.005, *p < 0.05. See also Figurecoverage of tumor blood vessels (Figure 6G). Interestingly, the
overall level of hypoxia was decreased, as shown by staining
with piminidazole (Figures 6H, 6I, and S6H). Consistent with bet-
ter perfusion, the overall expression of Vegfa mRNA in the total
tumor lysate is also decreased in VEGFfl/fldlckCRE mutant mice
(Figure 6J).
The lower levels of infiltrating lymphocytes in tumors in
VEGF-A mutant animals suggests that VEGF-A secreted by
CD8+ T cells might affect T cell homing through endothelial
barriers. An in vitro migration assay performed with T cells
isolated from VEGF-A mutant mice shows impaired migration
across a primary endothelial cell monolayer after culture in
hypoxia, supporting this hypothesis (Figure 6K), and gave
results similar to those seen in the same experimental cocul-
ture model described above employing HIF-1a-deficient
CD8+ T cells.
We then explored mechanisms involved in cell migration:
T cell-derived VEGF-A induced VE-cadherin endocytosis in
endothelial cells, and gave rise to a higher expression of the
adhesion molecule VCAM-1 (Figure 6L), an observation consis-
tent with the increased homing to tumors of VEGF-A-expressing
T cells.
To determine whether the described vascular changes,
consistent with vascular normalization, affect the delivery and
efficacy of chemotherapies to the tumor, we administered cyclo-
phosphamide tomutant and control tumor-bearingmice. Loss of
T cell-derived VEGF-A increased the chemotherapeutic effect of
the treatment (Figure 6M); as we did not assay for total amount
of cyclophosphamide in the treated tumors, this could be the
result of a change in delivery of the molecule or a change in a
secondary mediator of cytotoxicity.th and Normalizes Tumor Vasculature
WT recipient mice harboring B16-OVA tumors (n = 6). Left: tumor growth on
GFfl/fldlckCRE (blue), VEGFfl/fl littermate controls (gray), and WT c57/bl6 control
mor weights at the endpoint of the experiment (n > 13 per group, error bars
mor infiltration in mutant mice (blue) and littermate controls (black) by flow
tomato lectin-Dylight-594). Right: analyses of vessel length, percent perfused
ontrol (black) mice injected with tomato lectin-Dylight-594. The means of these
mice per group, error bars represent SEM).
d genotypes (red = tomato lectin-Dylight-594, green = a-SMA-AF488). Right:
oup, error bars represent SEM).
azole (green).
r group, error bars represent SEM).
epresent SD).
cells through a confluent layer of primary endothelial cells (n = 4, error bars
-1 (right) expression on MS-1 endothelial cells after 2 hr of treatment with re-
of VE-cadherin and VCAM-1 after 2 hr of coculture with CD8+ lymphocytes of
le control (n = 3, left) or cyclophosphamide (170 mg/kg, n = 7, right). Error bars
odel of spontaneous mammary adenocarcinoma (MMTV-PYMT) (error bars
ce per group).
icated genotypes.
es, statistical analysis was performed by two-way ANOVAwith Sidak correction
s S5 and S6.
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VEGF-A Deletion in T Lymphocytes Accelerates
Tumorigenesis
To ascertain the role of T cell-derived VEGF-A in a spontaneous
transgenic model of cancer, we employed the MMTV-PyMT
model of multifocal mammary adenocarcinoma (Guy et al.,
1992) backcrossed to a C57/Bl6 background (Davie et al.,
2007). Tumor latency, or time to the first palpable tumor, is
similar in VEGF-A mutant or WT littermate controls (Figure 6N).
However, at 17 weeks of age, total tumor mass is significantly
increased in mice lacking T cell-derived VEGF-A (Figure 6N),
and tumorigenic progression is significantly advanced when
scored histologically (Figure 6O).
DISCUSSION
There is a wealth of cell types that express HIF transcription fac-
tors in solid tumors. This is due to both the hypoxic nature of solid
tumors themselves and to other mechanisms for inducing HIF
expression, e.g., cytokine induction of HIF1A transcription.
A key to a better understanding of and, ultimately, therapy for
cancer is an increased characterization of the interactions be-
tween the varying responses of differing cell types in tumors to
the physiological challenges of malignant growth.
We show here that CD8+ T cells express both of the primary
HIF-a transcription factors. We also show that following activa-
tion, the angiogenic factor VEGF-A is produced at high levels
in CD8+ T cells. Although HIF-1a expression in T cells is linked
with a number of mechanisms for expression of T cell effector
molecules, we have now demonstrated that at least one part of
the role for HIF-1a in CD8+ T cells is to regulate a VEGF-A
response, one that in turn directly modulates tumorigenesis.
It has been shown that VHL deficiency in T cells promotes the
acquisition of effector function, leading to enhanced viral clear-
ance but also an exacerbated immune response (Doedens
et al., 2013). Deficiency of the three oxygen-sensing prolyl-hy-
droxylase enzymes (PHD1, PHD2, and PHD3) in T cells also pro-
motes T cell effector function (Clever et al., 2016). However, it is
also clear that the loss of these negative regulators affects a
range of downstream functions in cells and tissues.
The HIF-1a-driven transcriptional program that drives glyco-
lytic metabolism under hypoxia is impaired in HIF-1a-deficient
T cells, and it is clear that a high glycolytic rate is a prominent
feature of effector CD8+ T cells (Cham and Gajewski, 2005;
Chang et al., 2013). Here, we show that HIF-1a is essential for
controlling effector cell differentiation, migration, and function,
as well as the expression of numerous costimulatory and
exhaustion-related receptors in the tumor microenvironment.
Specific HIF-1a deletion in T cells resulted in defective effector
differentiation and accelerated tumor growth, once again
demonstrating that the contribution of HIF to cancer progression
is dependent on the cellular context.
We found that HIF-1a deletion resulted in impaired expression
of a set of proteins critically involved in CTL-mediated tumor
rejection. The production of effector cytokines, including IFNg
and TNFa and cytolytic molecules such as granzyme B, were
reduced as a result of HIF-1a genetic ablation. These immuno-
logic molecules are key in immunosurveillance (Kaplan et al.,
1998; Shankaran et al., 2001). Costimulatory and checkpoint
receptors, such as CD137, GITR, and OX40, and TIM3, PD-1,680 Cancer Cell 32, 669–683, November 13, 2017CTLA-4, and LAG-3 are another set of HIF-1a-dependent pro-
teins expressed by CTLs and involved in the fine-tuning of the
immune response. Due to the inhibitory role of checkpoint recep-
tors on T cells, they are targets for immunotherapy (Sharma and
Allison, 2015). Among them, we identified that PD-1 expression
in tumor-infiltrating lymphocytes was HIF-1a dependent, an
important observation given that PD-1 identifies the patient-spe-
cific CD8+ tumor-reactive TIL repertoire (Gros et al., 2014). This
differs from the data described in Doedens et al. (2013), where
we saw that downregulation of PD-1 was VHL dependent but
that this was not ablated in VHL/HIF-1a/HIF-2a triple-deficient
cells; this result thus indicates that PD-1 downregulation is not
due to the direct activity of either of the HIFa factors.
After activation upon antigen presentation in secondary
lymphoid organs, T cells home to tumors. Different subsets of
T cells found in tumors can correlate with differing clinical out-
comes and prognosis (Galon et al., 2013). As a result of Hif1a
deletion in T cells, the ratio of CD8+ to FOXP3+ cells in TILs
was significantly reduced. We found that this is correlated with
impaired CD8+ T cell homing to tumors. This was consistent
with our finding that CD8+ T cells lacking HIF-1a exhibit reduced
migration through endothelial barriers.
FOXP3+ regulatory T regulatory (Treg) cells have an important
role in immune homeostasis and cancer. The VHL-HIF axis is
essential for Treg function, as HIF-1a promotes FOXP3 protea-
somal degradation (Dang et al., 2011; Shi et al., 2011) and binds
to the IFNg promoter to drive T helper 1 responses (Lee et al.,
2015). We show a decreased ratio of IFNg+ to FOXP3+ cells in
CD4+ TILs lacking HIF-1a, which could further contribute to the
observed accelerated tumor growth. This supports a model
wherein HIF-1a increases overall effector T cell response. We
show here also that HIF-1a can influence immunotherapy, an
important observation given the recent success of autologous
cell-based cancer immunotherapies (June et al., 2015).
Immunological and angiogenic pathways influence many as-
pects of cancer development, and their interrelationships are
complex. We provide evidence that low levels of VEGF-A and
high levels of CD8 in the tumor microenvironment are predictors
of disease-free survival in breast cancer patients, corroborating
previous studies (DeNardo et al., 2011; Linderholm et al., 2003).
Our data show that the level of VEGF-A in tumors inversely cor-
relates with the presence of CD8+ T cells. As the primary source
of VEGF-A in a tumor will often be the malignant cells them-
selves, the relationship between the tumor, infiltrating TILs,
and the production of VEGF-A is difficult to place in an etiologic
order given our observations.
However, we show that Vegfa deletion in CD8+ T cells leads to
enhanced tumor growth. This does not appear to be due to an
intracrine effect of VEGF-A in CD8+ T cells, and we rule out a
cell-intrinsic defect of VEGF-deficient CTLs in the acquisition
of an effector phenotype as a direct explanation for the
enhanced tumor growth. VEGF-A production in tumors has
been linked to CD4+ FOXP3+ Treg cell abundance (Hansen
et al., 2012; Terme et al., 2013) and decreased infiltration by
tumor-reactive CD8+ T cells (Peng et al., 2016). VEGF-A produc-
tion by FOXP3+ Treg cells also contributes to tumor angiogen-
esis in vivo (Facciabene et al., 2011).
We found that VEGF-A-deficient CD8+ T cells do not infiltrate
tumors efficiently. VEGF-A is known to be an important
regulator of tumor/endothelial cell adhesion properties, and
plays a crucial role in the interactions between immune and
vascular cells, acting to promote recruitment (Detmar et al.,
1998; Kim et al., 2001; Melder et al., 1996). Systemic chronic
blockade of VEGF-A has been shown to increase T cell homing
to tumors (Motz et al., 2014). Our data would indicate that these
previously documented effects are not related to the expres-
sion of VEGF-A in T cells themselves, but are likely part of a
signaling/homing mechanism in the tumor cells or in other
stromal cells.
We show that loss of T cell-derived VEGF-A gives rise to
increased tumor oxygenation/perfusion, increased pericyte
coverage of tumor blood vessels, and accelerated tumor
growth. Vascular normalization is usually associated with
decreased hypoxia, better perfusion of the tumor, and a shift
in cancer cell metabolism, although it is clear that vascular
normalization does not always lead to increased tumor growth
and can also result in reduced or unaffected growth (Carmeliet
and Jain, 2011; Claesson-Welsh and Welsh, 2013). Tumor
response to chemotherapy is known to be affected by the
levels of oxygenation and the ability of the vessel network to
deliver drugs (Goel et al., 2012). In this context, we show that
mice lacking T cell-derived VEGF-A are more sensitive to
chemotherapy. As a result of better perfusion, hypoxia and,
thus, VEGF-A expression by other cells infiltrating the tumor
would also be reduced. Among them, macrophages actively
contribute to the angiogenic switch (Lin et al., 2006) by
secreting VEGF-A (Stockmann et al., 2008). Lymphocyte-
derived VEGF-A effects on macrophages and lymphocyte-
macrophage interactions could further explain the observed
vascular phenotype (Ramello et al., 2014), and this will be an
important subject for future investigation.
Our findings provide further rationale for the ongoing clinical
evaluation of combinatorial therapies comprising immunother-
apies and anti-angiogenic approaches (Hodi et al., 2014; Wu
et al., 2016). In summary, we show by T cell-specific gene
deletion that HIF-1a is an essential regulator of T cell effector
responses in the tumor microenvironment. Furthermore, we
show that this occurs in part, but not solely, through HIF-1a
regulation of VEGF-A; and that VEGF-A in effector CD8+ T cells
contributes to T cell infiltration, tumor vascularization, and tumor
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-mouse CD62L (clone MEL-14) Biolegend Cat# 104428
Anti-mouse CD44 (clone IM-7) Biolegend Cat# 103032
Anti-mouse CD8 (clone 53-6.7) Biolegend Cat# 100723
Anti-mouse CD3 (clone 17A2) Biolegend Cat# 100237
Anti-mouse CD4 (clone GK1.5) Biolegend Cat# 100408
Anti-mouse CD137 (clone 17B5) Biolegend Cat# 106110
Anti-mouse CD45.1 (clone A20) Biolegend Cat# 110728
Anti-mouse CD45.2 (clone 104) Biolegend Cat# 109814
Anti-mouse PD-1 (clone 29F.1A12) Biolegend Cat# 135214
Anti-mouse OX40 (clone OX-86) Biolegend Cat# 119414
Anti-mouse TIM-3 (clone B8.2C12) Biolegend Cat# 134006
Anti-mouse LAG-3 (clone C9B7W) Biolegend Cat# 125204
Anti-mouse GITR (clone DTA-1) Biolegend Cat# 126310
Anti-mouse Granzyme B (clone GB11) Biolegend Cat# 515406
Anti-mouse TNFa (clone MP6-XT22) Biolegend Cat# 506313
Anti-mouse IFNg (clone XMG1.2) Biolegend Cat# 505808
Anti-mouse CD25 (clone 3C7) Biolegend Cat# 101910
Anti-mouse CD69 (clone H1.2F3) Biolegend Cat# 104507
Anti-mouse VCAM-1 (clone MVCAM.A) Biolegend Cat# 105718
Anti-mouse VE-Cadherin (clone BV13) Biolegend Cat# 138010
Anti-mouse/Rat FOXP3 (clone FJK-16 s) Ebioscience Cat# 17-5773
Anti-mouse F4/80 Microbeads Miltenyi Cat# 130-110-443
Anti-mouse CD8 Microbeads Miltenyi Cat# 130-049-401
Anti-mouse CD4 Microbeads Miltenyi Cat# 130-049-201
Anti-mouse rabbit polyclonal HIF-1a Novus Cat# NB100-449
Anti-mouse rabbit polyclonal HIF-2a Novus Cat# NB100-122
Anti-mouse rabbit polyclonal HDAC1 Abcam Cat# Ab19845
Anti-mouse rabbit polyclonal b-actin Abcam Cat# ab8227
Anti-rabbit IgG HRP secondary antibody RnD Cat# HAF008
Anti-mouse CTLA-4 (clone 9H10) BioXCell Cat# BE0131
Anti-mouse PD-1 (clone RMP1-14) BioXCell Cat# BE0146
Polyclonal Syrian hamster IgG BioXCell Cat# BE0087
Rat IgG2a isotype control BioXCell Cat# BE0089
Anti-mouse SMA (clone 1A4) Sigma Cat# A5228
Anti-mouse IgG AF488 secondary antibody ThermoFisher Cat# R37120
LEAF purified anti-mouse CD3 Biolegend Cat# 100331
LEAF purified anti-mouse CD28 Biolegend Cat# 102102
Chemicals, Peptides, and Recombinant Proteins
Ovalbumin (257-264) chicken Sigma Cat# S7951
Recombinant mouse IL-2 Biolegend Cat# 575406
Recombinant mouse VEGF-A RnD Cat# 493-MV
Golgi stop protein transport inhibitor BD Cat# 554724
Cell stimulation cocktail eBioscience Cat# 00-4970-03
Cyclophosphamide Sigma Cat# C7397
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Histoclear II National diagnostics Cat# HS-202
G418 Geneticin ThermoFisher Cat# 10131027
2-Mercaptoethanol ThermoFisher Cat# 21985023
Critical Commercial Assays
RNeasy mini kit QIAGEN Cat# 74106
DNeasy kit QIAGEN Cat# 69506
NE-PER Nuclear and Cytoplasmic Extraction Reagents Thermo Scientific Cat# 78833
Seahorse Bioassay Agilent Cat# 102340
Seahorse cell energy phenotype kit Agilent Cat# 103325
Superscript III First strand synthesis kit ThermoFisher Cat# 18080051
DC Protein Assay BioRad Cat# 5000111
ECL prime western blotting GE Healthcare Cat# RPN2232
U-PLEX mouse VEGF-A Assay MSD Cat# K152-UVK
FOXP3 staining buffer set eBioscience Cat# 00-5523-00
Intracellular Fixation and Permeabilization buffer set ThermoFisher Cat# 88-8824-00
Absolute counting beads ThermoFisher Cat# C36950
Hypoxyprobe kit Hpi Hypoxyprobe Cat# HP6
DyLight 594 labeled Lycopersicon Esculentum lectin Vector laboratories Cat# DL-1177
Prolong Gold with DAPI ThermoFisher Cat# P36941
CFSE cell proliferation kit ThermoFisher Cat# C34554
LIVE/DEAD fixable violet kit ThermoFisher Cat# L34955
Experimental Models: Cell Lines
MS-1 ATCC Cat# CRL-2279
B16-F10 ATCC Cat# CRL-6475
LLC ATCC Cat# CRL-1642
EG7-OVA ATCC Cat# CRL-2113
Mouse primary T lymphocytes N/A N/A
Experimental models: Organisms/Strains
C57BL/6J The Jackson Laboratory 000664
Hif1atm3Rsjo In-house N/A
Epas1tm1Mcs In-house N/A
Vegfatm2Gne In-house N/A
Tg(Lck-icre)3779Nik The Jackson Laboratory 012837
Tg(MMTV-PyVT)634Mul The Jackson Laboratory 002374
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze The Jackson Laboratory 007909
PtprcaPepcb/BoyJ The Jackson Laboratory 002014
Tg(TcraTcrb)1100Mjb The Jackson Laboratory 003831
Oligonucleotides
Primers (RT-PCR), see Table S2 Sigma-Aldrich Custom
Primers (Deletion efficiency), see Table S3 IDT Custom
Deposited Data
Uppsala breast cancer cohort NCBI Gene Expression Omnibus GSE3494
Phase III Docetaxel+Sunitinib trial NCBI Gene Expression Omnibus GSE54323
Phase II PROMIX Bevacizumab trial NCBI Gene Expression Omnibus GSE87455CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the LeadContact: Randall S.
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EXPERIMENTAL MODELS AND SUBJECT DETAILS
Animal Models
Mice carrying Hif1a, Epas1 and VEGF-A loxP-flanked alleles were crossed with dlck-cre or LysM-cre mice to obtain T cell specific
gene deletion. Mice were backcrossed over ten generations to the C57bl/6 background. OT-1 mice containing transgenic inserts
for mouse TCR-Va2 and TCR-Vb5 genes that recognise ovalbumin residues 257-264 (SIINFEKL) were crossed with CD45.1,
Rosa-TdTomato, HIF-1afl/fldlckCRE, VEGFfl/fldlckCRE mice or their combinations. VEGFfl/fldlckCRE mice were also crossed with trans-
genic mice expressing the polyoma middle T (PyMT) oncoprotein under the promoter of the mouse mammary tumor virus (MMTV)
long terminal repeat (c57bl/6). Only female mice hemizygous for the PYMT oncogene were included in the tumor experiments. In all
experiments, male and female mice between 6 and 20 weeks were used. Littermates negative for the cre recombinase expression
were used as wild type controls. All experiments were carried out under license and in accordance with the ethical policies of the UK
Home Office and the University of Cambridge, and in accordance with the relevant laws and regulations of the UK and EU.
Experiments were approved by the University of Cambridge Animal Welfare Ethical Review Board (AWERB).
Cell Culture and Cellular Assays
Mouse splenic CD8+ T-lymphocytes were isolated with anti-mouse CD8amicrobeads (Miltenyi) on aMACS column. CD8+ T-lympho-
cytes were activated with plate-bound aCD3 (5 mg/ml, Biolegend) and soluble aCD28 (1mg/ml, Biolegend) for 48 h. For activation of
OT-I CD8+ T-cells, total splenocytes from OT-I mice were cultured with SIINFEKL peptide (Sigma). Culture media was RPMI-1640
containing 2 mM glutamine (Gibco), 10% FBS, 25 mM HEPES, 1% penicillin-streptomycin (Gibco), 50 mM b-mercaptoethanol
(Gibco). Following activation, CD8+ T-lymphocytes were expanded for 5 days in the presence of 20 ng/ml recombinant murine
IL-2 (Biolegend) and cultured under 21%, 5% or 1% oxygen conditions. For hypoxia experiments, cells were transferred into a
Ruskinn Sci-tive hypoxia workstation.
LLC, MS-1 and B16-F10 cell lines were cultured at 37 C with high glucose DMEM (Gibco) supplemented with 10% FBS. B16-OVA
culture media was supplemented with 0.8 mg/ml of G418 (Gibco).
Genomic Analyses of Breast Cancer Samples
Clinical cohorts: Gene-expression profiled breast cancer tissues from a population-based and well-annotated cohort of Swedish
patients was used as previously described (the Uppsala cohort, n=251, (Miller et al., 2005). In brief, RNA was extracted from freshly
frozen tumor tissue and profiled on Affymetrix HG-U133A and HG-U133B arrays. Affymetrix CEL files are available at the Gene
Expression Omnibus Database under accession number GSE3494. Additionally, gene expression data from a translational substudy
of a Phase 3 study of docetaxel with or without sunitinib as first line treatment of metastatic breast cancer was used (Bergh et al.,
2012; Foukakis et al., 2015). In this study, transcriptomic profiling of metastatic tumor aspiration biopsies was carried out at baseline
and 14 days after start of treatment (Foukakis et al., 2015), Gene Expression Omnibus Database accession number GSE54323. Last,
in the Phase 2 PROMIX trial, patients (n=150) with locally advanced breast cancer were treated preoperatively with two cycles of
chemotherapy with epirubicin and docetaxel, followed by four additional cycles of the same chemotherapy with the addition of
bevacizumab (Clinicaltrials.gov identifier NCT00957125). Gene expression data at all three time points were available for 36 patients.
Themedian age at the time of diagnosis was 49 years (range 33-65). Themedian tumor size at baseline was 56mm (range 30-110). All
tumors were HER2 negative, 24 of the tumors were ER positive and 11 ER negative (one with unknown ER status). After a median
follow up time of 48 months, 8 patients had relapsed and 3 of them had died of breast cancer. Gene expression profiling of tumor
core biopsies was performed at baseline, after two cycles of chemotherapy and at surgery (Gene Expression Omnibus Database
accession number GSE87455). Informed consent was obtained from all subjects.
METHODS DETAILS
Metabolism Assays
Extracellular acidification rate (ECAR) and oxygen consumption rates (OCR) were measured using a XF24 3 Extracellular Flux
Analyzer (Seahorse). 0.5 x 106 CD8+ T cells per well were plated on poly-D-lysine coated plates, in XF media (non-buffered RPMI
base medium, 25mM glucose, 2mM glutamine and 1 mM sodium pyruvate). Assays were performed with a Seahorse Cell Energy
Phenotype Test Kit, and ECAR and OCR were measured simultaneously before and after injection of Olygomycin (1 mM) and
FCCP (1 mM). For experiments performed under 1% O2, the XF24 3 analyzer was placed inside a hypoxic globe box (Coy).
Glucose and lactate levels were determined with a Dade-Behring Dimension RXL autoanalyser (Siemens). VEGF-A levels in media
were measured with a VEGF-A immunoassay kit (MSD). Protein levels were normalized to viable cell counts performed on an
ADAM-MC automated cell counter (NanoEnTek). T cell proliferation was measured by CFSE dilution assay 72 hours after T cell
activation with plate-bound aCD3 (5 mg/ml, Biolegend) and soluble aCD28 (1mg/ml, Biolegend).
Cytotoxicity Assays
The in vitro cytotoxicity assay shown in Figure S2I was performed by co-culturing EG7-OVA target cells with control or mutant OT-1
CD8+ T cells, at different effector to target (E:T) ratios for 24 hours, under 21%or 1%O2 . The percent cell specific killing of eachCD8
+
T cell genotype was calculated by flow cytometry, and counting beads (ThermoFisher) were used as normalizing controls. The in vitroe3 Cancer Cell 32, 669–683.e1–e5, November 13, 2017
antigen-specific killing assay shown in Figure S6E was performed using a 1:1 mix of CFSE labeled peptide-pulsed cells (CFSElo) and
control cells (CFSEhi) as targets. The percent cell specific killing of each CD8+ T cell genotype was calculated based on the CFSE
analysis by flow cytometry after a 4 hour co-culture of CD8+ CTLs and target cells.
Transendothelial T-Cell Migration Assays
25x104 mutant or control a CD3/CD28 activated CD8+ CTLs were subjected to 1% O2 for 24 hours and then cultured in a Boyden
chamber on top of a confluent layer of primary endothelial cells isolated from lungs of wild type mice, as described before
(Branco-Price et al., 2012). 12 hours later T cells in the bottom well were counted.
Surface VCAM-1 and VE-Cadherin Analysis
MS-1 endothelial cells (ATCC) were cocultured with VEGFfl/fldlckCRE or VEGFfl/fl control CTLs for 2 hours, stained with fluorescent-
labeled antibodies (Biolegend), and analyzed by flow cytometry. Recombinant mouse VEGF-A (Sigma) was used at 20 ng/mL.
Flow Cytometry
Cells were stained with LIVE/DEAD Violet (Life Technologies) before antibody staining. The following fluorophore-conjugated
antibodies were used (Biolegend): a-CD62L, CD44, CD8, CD3, CD4, CD8, CD137, CD45.1, PD-1, OX40, GITR, TIM-3, LAG-3,
Granzyme B, TNFa, IFNg, CD25, and CD69. a-FOXP3 was from eBiosciences. For TNFa and IFNg intracellular staining, cells
were restimulated with SIINFEKL peptide (Sigma) for 4 hours in the presence of Golgi-stop (BD) or cell stimulation cocktail
(eBiosciences) and then fixed and permeabilized with Fix/perm buffer (eBiosciences) before intracellular staining and acquisition
on a Fortessa (BD). Data was analyzed by FlowJo (TreeStar).
For flow cytometric analyses of TILs, excised tumors were minced finely with a scalpel blade in a Petri dish, and incubated for
25 minutes at 37C in Collagenase-D and DNAse-I (Roche) in RPMI before passage through a 70-mm cell strainer (BD) to obtain
single-cell suspensions and perform antibody staining.
QRT-PCR and Western Blotting
Total RNA was extracted from isolated CD8+ T cells (RNeasy kit, Qiagen) and 1 mg of RNA was used for cDNA synthesis (First-Strand
Synthesis kit, Invitrogen). Tumor infiltratingmacrophages and lymphocyteswere positively isolated from single-cell suspensions with
anti-mouse F4/80, CD8a or CD4microbeads (Miltenyi) on aMACS column. Real time PCRwas performed with SYBR green (Thermo)
in a StepOnePlus system (Applied Biosystems). Samples were run in technical triplicates. Data was normalized to 18S rRNA orHPRT
expression. The primers used are shown in the Table S2.
To calculate the gDNA deletion efficiency, total DNA was extracted with the DNeasy kit (Qiagen) and the primers shown in the
Table S3 were used in a Taqman RT-PCR mastermix (ThermoFisher).
For immunoblotting, nuclear and cytosolic fractions were prepared (NE-PER kit, Thermo Scientific), quantified by the DC-Protein
Assay (BioRad), and separated by SDS–PAGE on a Nu-Page 3-8% Tris acetate gel (Life technologies). Proteins were transferred to
PVDF trans-blot membranes (Bio-rad) and blocked in 5% milk prepared in phosphate-buffered saline (PBS) containing 0.05%
Tween-20. Membranes were incubated with primary antibodies overnight at 4C and horseradish peroxidase (HRP)-conjugated
secondary antibody at RT, revealed with ECL Prime (GE Healthcare) and imaged with a Fusion FX analyser (Vilber Lourmat). The
following primary antibodies were used at a dilution of 1:1000: HIF-1a (Novus), HIF-2a (Novus), HDAC1 (abcam), b-actin (abcam).
Tumor Growth
A total of 0.5 3 106 LLC or B16-F10 cells were injected subcutaneously into the flank in 100 mL of PBS. Mice and tumor size were
monitored every other day and mice were sacrificed when tumor size reached 144 mm2. Tumor sizes were measured using a digital
caliper and tumor volumes calculated with the formula 1/2(length x width2).
Adoptive Cell Transfer
Total splenocytes isolated from or OT-1-VEGFfl/fldlckCRE mice, and OT-1-HIF-1afl/fl or OT-1-VEGFfl/fl littermate controls were
activated with SIINFEKL peptide in the presence of IL-2. Five days later, total splenocytes were inoculated intravenously (1x106 cells
per mouse) into recipient mice carrying subcutaneous B16-OVA tumors (5x105 cells injected 5 days before T cell transfer). For the
in vivomigration experiment, a 1:1 pool of mutant (CD45.1+TdTomato+OT-1+HIF-1afl/fldlckCRE) and control (CD45.1+OT-1+HIF-1afl/fl)
CD8+ T cells (1x106 cells per genotype) was intravenously transferred into CD45.2+ B16-OVA tumor-bearing WT mice. Spleens,
lymph nodes (LN) and tumors were collected 48 hours after the co-transfer.
In Vivo Immunotherapy and Chemotherapy
Checkpoint blockade therapy consisting on a combination of 200 mg of aCTLA-4 (clone 9H10, BioXCell) and 200 mg of aPD-1
(RMP1-14, BioXCell) antibodies per dose or isotype control antibodies (Syrian hamster IgG and Rat IgG2a, respectively, BioXCell)
was administered on days 5, 7 and 9 after tumor injection, which consisted on 0.5x106 MC38 colon carcinoma cells injected
subcutaneously.
The treatment with chemotherapywas administered on days 5, 7 and 9 after the subcutaneous injection of 0.5x106 LLC tumor cells.
Cyclophosphamide (i.p., 170mg/kg) was purchased from Sigma.Cancer Cell 32, 669–683.e1–e5, November 13, 2017 e4
Histology, Immunofluorescence and In Vivo pO2 Measurements
Mammary glands were collected and fixed in 4%paraformaldehyde (Santa Cruz Biotechnology) for 24 hours, washed in 70%ethanol
and embedded in paraffin. 10 mm sections were deparaffinized with Histoclear II (National diagnostics) and rehydrated in graded
ethanol. Sections were stained with haematoxylin/eosin and scored histologically as previously described (Lin et al., 2003). For
vascular staining, eachmousewas injected intravenously with 100 mg of DyLight 594 labeled Lycopersicon Esculentum lectin (Vector
laboratories) 5 minutes before sacrifice. 10 mm sections were mounted with ProLong Gold antifade mountant with DAPI
(ThermoFisher) and photographed with a Leica DMRB microscope. Vessel analyses were performed with ImageJ and a customized
software application fromWimasis. For pimonidazole staining, mice were injected with 60mg/kg bodyweight of pimonidazole hydro-
chloride (hpi Hypoxyprobe), 1 hour before tumor collection. Tissues were embedded in paraffin and pimonidazole adducts were
detected with a FITC-conjugated mouse IgG1 antibody at a 1:50 dilution (hpi Hypoxyprobe). Mouse a-SMA antibody (Sigma) was
used at a 1:100 dilution followed by anti-mouse AF-488 secondary antibody (Life technologies). Complete tumor section pictures
were taken by tiling acquisition with a Leica TCS SPE confocal microscope and hypoxic area percentages and pericyte coverage
were calculated with ImageJ.
Dissolved oxygen (pO2) was measured in complete cell culture medium under 21%, 5% and 1% O2 in a Ruskinn cell culture
workstation, and in the spleens and LLC subcutaneous tumors implanted in WT mice (n=2), by an Oxylite sensor equipped with a
needle-encased sensor. Two-tailed student T test was used for comparisons.
STATISTICAL ANALYSIS
Statistical Analysis
Data were analyzed in GraphPad Prism 6 software. Pairwise comparisons were performed using an unpaired Student’s t-test.
Grouped data were assessed by two-way ANOVA with Bonferroni’s correction, to adjust for multiple comparisons. Tumor volumes
were analyzed by two-way ANOVA followed by Sidak correction for multiple comparisons. Survival curves were compared with the
long-rank (Mantel-Cox) test. Statistical details of experiments can be found in the figure legends. n represents number of animals.
p values legend is: ****<0.00005, ***< 0.0005, **<0.005, *< 0.05, n.s.=not significant.
Clinical Gene-Expression Data Analysis
All analysis of the clinical gene-expression data was performed in R/Bioconductor. Probe intensities were extracted from Affymetrix
CEL files and background corrected, log2-transformed, normalized and summarized to probeset expression using the rma function
in the affy package with the default settings. Probesets were mapped to Entrez Gene ID and symbol using the hgu133a.db and
hgu133b.db annotation packages. When multiple probesets were mapped to the same Entrez Gene ID, the average expression
was used. PAM50 intrinsic subtype classification was performed. Statistical analysis: Survival analysis of the clinical gene-expres-
sion data was performed in R using the survival package with default settings.e5 Cancer Cell 32, 669–683.e1–e5, November 13, 2017
